N-(2-氮杂环庚烷-1-乙基)-N-异丙胺 | 532407-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: N-(2-氮杂环庚烷-1-乙基)-N-异丙胺
• 英文名称: N-(2-Azepan-1-ylethyl)-N-isopropylamine
• 英文别名: N-[2-(azepan-1-yl)ethyl]propan-2-amine
• CAS: 532407-05-9
• 化学式: C₁₁H₂₄N₂
• mdl: MFCD08691567
• 分子量: 184.32
• InChiKey: RMZFCHGMKNLUEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

文献信息

• 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
  申请人：Borthwick David Alan

  公开号：US20050004119A1

  公开（公告）日：2005-01-06

  The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.

  本发明涉及化合物(I)的配方、包含该化合物的药物组合物，以及使用该组合物治疗患有易于通过因子Xa抑制剂改善的疾病的患者的方法。
• 2-(3-SULFONYLAMINO-2-OXOPYRROLIDIN-1-YL)PROPANAMIDES AS FACTOR XA INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1444201B1

  公开（公告）日：2007-09-12
• COMPOSITIONS AND METHODS FOR TREATING ALCOHOL USE DISORDERS, PAIN AND OTHER DISEASES
  申请人：VM Discovery, Inc.

  公开号：EP2356109B1

  公开（公告）日：2016-12-07
• ANTIPATHOGENIC BENZAMIDE COMPOUNDS
  申请人：BURLI Roland W.

  公开号：US20080200465A1

  公开（公告）日：2008-08-21

  The present invention is related to methods of treating viral and protozoan infections in mammals using antipathogenic benzamide compounds having the formula wherein at least one of the R 1 groups is F, Cl, CN or CF 3 and R 2 , R 3 , Y, Z, m, and n are as defined herein.
• TrkB POSITIVE ALLOSTERIC MODULATORS
  申请人：Université de Strasbourg

  公开号：US20220389019A1

  公开（公告）日：2022-12-08

  The present invention relates to the field of pharmaceutical composition comprising “LIT-TB” derivatives. More particularly it relates to “LIT-TB” derivatives for use in the treatment of neurodegenerative diseases, and more particularly in the treatment of Huntington's disease. The invention also relates to the “LIT-TB” derivatives and preparation thereof.